Product Description
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pertechnetate)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Greece | Hong Kong | Hungary | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Fundacio De Recerca Clinic Barcelona-Institut Dâinvestigacions Biomediques August Pi I Sunyer
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Other
Phase 3: Bone Cancer
Phase 2: COVID-19|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-518974-15-01 | P4 |
Unknown Status |
Other |
2030-05-15 |
|
| 2021-006371-42 | P4 |
Active, not recruiting |
Unknown |
2027-01-18 |
|
| SOLLID | N/A |
Completed |
Other |
2022-06-30 |
|
| 99mTC thyroid scan in DTC | N/A |
Unknown status |
Thyroid Cancer |
2021-12-31 |